These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 19654036)

  • 41. Signal transducers and activators of transcription 5a-dependent cross-talk between follicular lymphoma cells and tumor microenvironment characterizes a group of patients with improved outcome after R-CHOP.
    Taskinen M; Valo E; Karjalainen-Lindsberg ML; Hautaniemi S; Meri S; Leppä S
    Clin Cancer Res; 2010 May; 16(9):2615-23. PubMed ID: 20388848
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.
    Marcus R; Imrie K; Solal-Celigny P; Catalano JV; Dmoszynska A; Raposo JC; Offner FC; Gomez-Codina J; Belch A; Cunningham D; Wassner-Fritsch E; Stein G
    J Clin Oncol; 2008 Oct; 26(28):4579-86. PubMed ID: 18662969
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of cyclosporin A used alone and in combination with either 2-chlorodeoxyadenosine or fludarabine on normal and chronic myelogenous leukemia progenitors in vitro.
    Korycka A; Robak T
    Arch Immunol Ther Exp (Warsz); 2003; 51(1):61-7. PubMed ID: 12691305
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro assessment of bone marrow endothelial colonies (CFU-En) in non-Hodgkin's lymphoma patients undergoing peripheral blood stem cell transplantation.
    Lanza F; Campioni D; Punturieri M; Moretti S; Dabusti M; Spanedda R; Castoldi G
    Bone Marrow Transplant; 2003 Dec; 32(12):1165-73. PubMed ID: 14647271
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
    Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
    Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.
    Martin P; Byrtek M; Dawson K; Ziemiecki R; Friedberg JW; Cerhan JR; Flowers CR; Link BK
    Cancer; 2013 Dec; 119(23):4129-36. PubMed ID: 24006156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma.
    Derenzini E; Casadei B; Broccoli A; Gandolfi L; Pellegrini C; Zinzani PL
    Br J Haematol; 2014 Aug; 166(4):625-8. PubMed ID: 24750128
    [No Abstract]   [Full Text] [Related]  

  • 48. CHOP chemotherapy followed by Rituximab consolidation as first line treatment in patients with follicular lymphoma. Long-term follow-up of a phase 2 trial.
    Jäger G; Quehenberger F; Linkesch W; Neumeister P
    Eur J Haematol; 2007 May; 78(5):453-5. PubMed ID: 17419745
    [No Abstract]   [Full Text] [Related]  

  • 49. Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
    Wilder DD; Ogden JL; Jain VK
    Clin Lymphoma; 2002 Mar; 2(4):229-37. PubMed ID: 11970762
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
    Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A
    J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
    Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
    J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin T levels.
    Niitsu N; Khori M; Hayama M; Kajiwara K; Higashihara M; Tamaru J
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):697-702. PubMed ID: 15701858
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful treatment of lymphoma with fludarabine combined with rituximab after immune thrombocytopenia induced by fludarabine.
    Tsutsumi Y; Kanamori H; Minami H; Musashi M; Fukushima A; Ehira N; Yamato H; Obara S; Ogura N; Tanaka J; Asaka M; Imamura M; Masauzi N
    Ann Hematol; 2005 Apr; 84(4):269-71. PubMed ID: 15592832
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment.
    Lysak D; Koza V; Steinerova K; Jindra P; Vozobulova V; Schutzova M
    Ann Hematol; 2005 Jul; 84(7):456-61. PubMed ID: 15770494
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hematopoietic damage prior to PBSCT and its influence on hematopoietic recovery.
    del Cañizo MC; Lopez N; Vazquez L; Fernandez ME; Ana B; Caballero MD; Amigo ML; Mateos MV; Gutierrez N; San Migue JF
    Haematologica; 1999 Jun; 84(6):511-6. PubMed ID: 10366794
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Progenitor content of autologous grafts: mobilized bone marrow vs mobilized blood.
    Dahl E; Burroughs J; DeFor T; Verfaillie C; Weisdorf D
    Bone Marrow Transplant; 2003 Sep; 32(6):575-80. PubMed ID: 12953129
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Measurement of long-term culture initiating cells (LTC-ICs) using limiting dilution: comparison of endpoints and stromal support.
    Weaver A; Ryder WD; Testa NG
    Exp Hematol; 1997 Dec; 25(13):1333-8. PubMed ID: 9406992
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinical outcomes of different regimens for non-Hodgkin's lymphoma with bone marrow involvement: analysis of 148 cases].
    Li QC; Yuan XL; Wang YF; Zou DH; Zhao YZ; Qiu LG
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):254-7. PubMed ID: 18361837
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of myelotoxicity in cotton rats (Sigmodon hispidus) exposed to environmental contaminants. I. In vitro bone-marrow progenitor culture.
    Kim S; Stair EL; Lochmiller RL; Lish JW; Qualls CW
    J Toxicol Environ Health A; 2001 Jan; 62(2):83-96. PubMed ID: 11209823
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
    Tsimberidou AM; McLaughlin P; Younes A; Rodriguez MA; Hagemeister FB; Sarris A; Romaguera J; Hess M; Smith TL; Yang Y; Ayala A; Preti A; Lee MS; Cabanillas F
    Blood; 2002 Dec; 100(13):4351-7. PubMed ID: 12393618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.